← Leaderboards
Christos Fountzilas
Roswell Park Cancer Institute Corp
$1,631,453
Attributed
$1,631,453
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $586K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,631,453 · 1
By mechanism
R37$1,631,453 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Andrei Bakin$2,370,189
- Josephia R Muindi$421,328
- Liya Ding$1,457,814
Others in their field
Other Rising Stars on “Analog”
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Michael George Natchus · Emory University$10,548,554
- Alexander Kolykhalov · Emory University$8,116,465
- Anil Gupta · Scripps Research Institute, The$7,340,144
- James M Balkovec · Hackensack University Medical Center$6,590,120
Research focus
AnalogAntineoplastic AgentsBiological MarkersBiomarker DrivenBiomarker IdentificationBiomarker SelectionBloodBraf GeneCancer CellCancer ModelCell DeathCellsChromatinChromatin StructureClinical ApplicationClinical BiomarkersClinical DataClinical EfficacyClinical ImplementationClinical TrialsCohortColorectal AdenocarcinomaColorectal CancerAmplifiers
Grant awards (3)
Novel synthetic lethality strategy for TP53 mutant colorectal cancer$542,949
R37 · FY2025 · CA · contact PI
Novel synthetic lethality strategy for TP53 mutant colorectal cancer$502,520
R37 · FY2024 · CA · contact PI
Novel synthetic lethality strategy for TP53 mutant colorectal cancer$585,984
R37 · FY2023 · CA · contact PI